133 related articles for article (PubMed ID: 6631718)
1. Stereoselective increase in propranolol bioavailability during chronic dosing in the dog.
Bai SA; Wilson MJ; Walle UK; Walle T
J Pharmacol Exp Ther; 1983 Nov; 227(2):360-4. PubMed ID: 6631718
[TBL] [Abstract][Full Text] [Related]
2. Stereochemical composition of propranolol metabolites in the dog using stable isotope-labeled pseudoracemates.
Walle T; Wilson MJ; Walle UK; Bai SA
Drug Metab Dispos; 1983; 11(6):544-9. PubMed ID: 6140137
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.
Walle T; Walle UK
Res Commun Chem Pathol Pharmacol; 1979 Mar; 23(3):453-64. PubMed ID: 461970
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective disposition of propranolol in rabbits. Role of presystemic organs and dose.
Marier JF; Pichette V; du Souich P
Drug Metab Dispos; 1998 Feb; 26(2):164-9. PubMed ID: 9456303
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective ring oxidation of propranolol in man.
Walle T; Walle UK; Wilson MJ; Fagan TC; Gaffney TE
Br J Clin Pharmacol; 1984 Nov; 18(5):741-8. PubMed ID: 6508983
[TBL] [Abstract][Full Text] [Related]
6. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics.
Vu VT; Bai SA; Abramson FP
J Pharmacol Exp Ther; 1983 Jan; 224(1):55-61. PubMed ID: 6848749
[TBL] [Abstract][Full Text] [Related]
7. Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing.
Lankford SM; Maskasame C; Bai SA
Drug Metab Dispos; 1994; 22(5):776-87. PubMed ID: 7835231
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of propranolol in the dog.
Tse FL; Sanders TM; Reo JP
Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
[TBL] [Abstract][Full Text] [Related]
9. Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.
Heinzow B; Corbett H; Constantinides S; Bourne R; McLean AJ
J Pharmacol Exp Ther; 1984 May; 229(2):509-14. PubMed ID: 6716273
[TBL] [Abstract][Full Text] [Related]
10. Oxidation of (R)- and (S)-propranolol in human and dog liver microsomes. Species differences in stereoselectivity.
von Bahr C; Hermansson J; Lind M
J Pharmacol Exp Ther; 1982 Aug; 222(2):458-62. PubMed ID: 7097564
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of the pharmacologically active 4'-hydroxylated metabolite of propranolol in the dog.
Christ DD; Walle UK; Oatis JE; Walle T
Drug Metab Dispos; 1990; 18(1):1-4. PubMed ID: 1970766
[TBL] [Abstract][Full Text] [Related]
12. Interaction between oral hydralazine and propranolol. II. Assessment of altered splanchnic blood flow as the determinant of altered presystemic extraction.
Corbett H; Cahill CM; Heinzow B; Harrison PM; Byrne AJ; McLean AJ
J Pharmacol Exp Ther; 1986 Nov; 239(2):517-21. PubMed ID: 3772806
[TBL] [Abstract][Full Text] [Related]
13. Stereochemistry of the in vivo disposition and metabolism of propranolol in dog and man using deuterium-labeled pseudoracemates.
Walle T
Drug Metab Dispos; 1985; 13(3):279-82. PubMed ID: 2861983
[No Abstract] [Full Text] [Related]
14. Stereoselective disposition and glucuronidation of propranolol in humans.
Silber B; Holford NH; Riegelman S
J Pharm Sci; 1982 Jun; 71(6):699-704. PubMed ID: 7097538
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective sulfation of R,S-4'-hydroxypropranolol by canine hepatic cytosol and partially purified phenolsulfotransferases.
Christ DD; Walle T
J Pharmacol Exp Ther; 1989 Dec; 251(3):949-55. PubMed ID: 2600823
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective binding of the (-)-enantiomer of propranolol to plasma and extravascular binding sites in the dog.
Bai SA; Walle UK; Wilson MJ; Walle T
Drug Metab Dispos; 1983; 11(4):394-5. PubMed ID: 6137350
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics and metabolism of a 4'-methylthio derivative of propranolol in the dog.
Bai SA; Easterling DE; Wilson MJ; Walle UK; Haney CA; Peet NP; Pruett JK; Walle T
Drug Metab Dispos; 1989; 17(5):495-505. PubMed ID: 2573492
[TBL] [Abstract][Full Text] [Related]
18. Presystemic and systemic glucuronidation of propranolol.
Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
[TBL] [Abstract][Full Text] [Related]
19. Stereoselective clearance and distribution of intravenous propranolol.
Olanoff LS; Walle T; Walle UK; Cowart TD; Gaffney TE
Clin Pharmacol Ther; 1984 Jun; 35(6):755-61. PubMed ID: 6734027
[TBL] [Abstract][Full Text] [Related]
20. Partial metabolic clearances as determinants of the oral bioavailability of propranolol.
Walle T; Walle UK; Olanoff LS; Conradi EC
Br J Clin Pharmacol; 1986 Sep; 22(3):317-23. PubMed ID: 3768243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
